Bird Flu
StormBio and Imperial Innovations Enter Agreement for Pandemic Influenza Treatment
Published in TB and Outbreaks Week, April 10th, 2007
This agreement will permit StormBio to develop a new class of therapeutics to save lives and reduce disability from flu and other inflammatory diseases.
The StormBio therapeutic will differ from current influenza treatments by targeting the body's over-reaction of the inflammatory process, without shutting down the immune response. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Bioterrorism
Aethlon Medical Responds to U.S. Government Initiative to Develop and Acquire Broad-Spectrum Biodefense Countermeasures - Bird Flu
HepaLife's Patented ''PBS-1'' Cells for Avian Flu Vaccines Outperform Current Cell System by 500% - Flu Vaccines
Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine - Flu Vaccines
MedImmune Licenses Reverse Genetics Technology to sanofi pasteur for Use in Influenza Vaccine Production - HIV/AIDS Co-Infection
Nutra Pharma Sponsors Educational Website about Tuberculosis (TB) in Conjunction with World TB Day - Leishmaniasis
OneWorld Health Selects Odyssey Research for Phase 4 Study in India - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
